Reply to Ruobing Lei, Yuehuan Li, and Yaolong Chen's Letter to the Editor re Katharina Beyer, Lisa Moris, Michael Lardas, et al. Updating and Integrating Core Outcome Sets for Localised, Locally Advanced, Metastatic, and Nonmetastatic Castration-resistant Prostate Cancer: An Update from the PIONEER Consortium. Eur Urol 2022;81:503-14. Improving the Methodological Quality of Prostate Cancer Core Outcome Sets in Future Updates

Katharina Beyer; Steven MacLennan; Mieke Van Hemelrijck

doi:10.1016/j.eururo.2022.05.014

Reply to Ruobing Lei, Yuehuan Li, and Yaolong Chen's Letter to the Editor re Katharina Beyer, Lisa Moris, Michael Lardas, et al. Updating and Integrating Core Outcome Sets for Localised, Locally Advanced, Metastatic, and Nonmetastatic Castration-resistant Prostate Cancer: An Update from the PIONEER Consortium. Eur Urol 2022;81:503-14. Improving the Methodological Quality of Prostate Cancer Core Outcome Sets in Future Updates

Katharina Beyer^* (Corresponding Author), Steven MacLennan, Mieke Van Hemelrijck

^*Corresponding author for this work

King's College London

Research output: Contribution to journal › Letter

Abstract

We thank Lei et al for their interest in our manuscript [1] and would like to take the opportunity to clarify their concerns regarding our methodology.

Original language	English
Pages (from-to)	e68-e69
Number of pages	2
Journal	European Urology
Volume	82
Issue number	3
Early online date	11 Aug 2022
DOIs	https://doi.org/10.1016/j.eururo.2022.05.014
Publication status	Published - 1 Sept 2022

Keywords

Abiraterone Acetate
Humans
Male
Outcome Assessment, Health Care
Prostatic Neoplasms
Prostatic Neoplasms, Castration-Resistant

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.eururo.2022.05.014Licence: Unspecified

Fingerprint

Dive into the research topics of 'Reply to Ruobing Lei, Yuehuan Li, and Yaolong Chen's Letter to the Editor re Katharina Beyer, Lisa Moris, Michael Lardas, et al. Updating and Integrating Core Outcome Sets for Localised, Locally Advanced, Metastatic, and Nonmetastatic Castration-resistant Prostate Cancer: An Update from the PIONEER Consortium. Eur Urol 2022;81:503-14. Improving the Methodological Quality of Prostate Cancer Core Outcome Sets in Future Updates'. Together they form a unique fingerprint.

Cite this

Beyer, K., MacLennan, S., & Van Hemelrijck, M. (2022). Reply to Ruobing Lei, Yuehuan Li, and Yaolong Chen's Letter to the Editor re Katharina Beyer, Lisa Moris, Michael Lardas, et al. Updating and Integrating Core Outcome Sets for Localised, Locally Advanced, Metastatic, and Nonmetastatic Castration-resistant Prostate Cancer: An Update from the PIONEER Consortium. Eur Urol 2022;81:503-14. Improving the Methodological Quality of Prostate Cancer Core Outcome Sets in Future Updates. European Urology, 82(3), e68-e69. https://doi.org/10.1016/j.eururo.2022.05.014

Reply to Ruobing Lei, Yuehuan Li, and Yaolong Chen's Letter to the Editor re Katharina Beyer, Lisa Moris, Michael Lardas, et al. Updating and Integrating Core Outcome Sets for Localised, Locally Advanced, Metastatic, and Nonmetastatic Castration-resistant Prostate Cancer: An Update from the PIONEER Consortium. Eur Urol 2022;81:503-14. Improving the Methodological Quality of Prostate Cancer Core Outcome Sets in Future Updates. / Beyer, Katharina (Corresponding Author); MacLennan, Steven; Van Hemelrijck, Mieke.
In: European Urology, Vol. 82, No. 3, 01.09.2022, p. e68-e69.

Research output: Contribution to journal › Letter

Beyer, K, MacLennan, S & Van Hemelrijck, M 2022, 'Reply to Ruobing Lei, Yuehuan Li, and Yaolong Chen's Letter to the Editor re Katharina Beyer, Lisa Moris, Michael Lardas, et al. Updating and Integrating Core Outcome Sets for Localised, Locally Advanced, Metastatic, and Nonmetastatic Castration-resistant Prostate Cancer: An Update from the PIONEER Consortium. Eur Urol 2022;81:503-14. Improving the Methodological Quality of Prostate Cancer Core Outcome Sets in Future Updates', European Urology, vol. 82, no. 3, pp. e68-e69. https://doi.org/10.1016/j.eururo.2022.05.014

Beyer K, MacLennan S, Van Hemelrijck M. Reply to Ruobing Lei, Yuehuan Li, and Yaolong Chen's Letter to the Editor re Katharina Beyer, Lisa Moris, Michael Lardas, et al. Updating and Integrating Core Outcome Sets for Localised, Locally Advanced, Metastatic, and Nonmetastatic Castration-resistant Prostate Cancer: An Update from the PIONEER Consortium. Eur Urol 2022;81:503-14. Improving the Methodological Quality of Prostate Cancer Core Outcome Sets in Future Updates. European Urology. 2022 Sept 1;82(3):e68-e69. Epub 2022 Aug 11. doi: 10.1016/j.eururo.2022.05.014

Beyer, Katharina ; MacLennan, Steven ; Van Hemelrijck, Mieke. / Reply to Ruobing Lei, Yuehuan Li, and Yaolong Chen's Letter to the Editor re Katharina Beyer, Lisa Moris, Michael Lardas, et al. Updating and Integrating Core Outcome Sets for Localised, Locally Advanced, Metastatic, and Nonmetastatic Castration-resistant Prostate Cancer: An Update from the PIONEER Consortium. Eur Urol 2022;81:503-14. Improving the Methodological Quality of Prostate Cancer Core Outcome Sets in Future Updates. In: European Urology. 2022 ; Vol. 82, No. 3. pp. e68-e69.

@article{6a1ba19484f84caf8d21a8d6ec74f888,

title = "Reply to Ruobing Lei, Yuehuan Li, and Yaolong Chen's Letter to the Editor re Katharina Beyer, Lisa Moris, Michael Lardas, et al. Updating and Integrating Core Outcome Sets for Localised, Locally Advanced, Metastatic, and Nonmetastatic Castration-resistant Prostate Cancer: An Update from the PIONEER Consortium. Eur Urol 2022;81:503-14. Improving the Methodological Quality of Prostate Cancer Core Outcome Sets in Future Updates",

abstract = "We thank Lei et al for their interest in our manuscript [1] and would like to take the opportunity to clarify their concerns regarding our methodology.",

keywords = "Abiraterone Acetate, Humans, Male, Outcome Assessment, Health Care, Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant",

author = "Katharina Beyer and Steven MacLennan and {Van Hemelrijck}, Mieke",

year = "2022",

month = sep,

day = "1",

doi = "10.1016/j.eururo.2022.05.014",

language = "English",

volume = "82",

pages = "e68--e69",

journal = "European Urology",

issn = "0302-2838",

publisher = "Elsevier",

number = "3",

}

TY - JOUR

T1 - Reply to Ruobing Lei, Yuehuan Li, and Yaolong Chen's Letter to the Editor re Katharina Beyer, Lisa Moris, Michael Lardas, et al. Updating and Integrating Core Outcome Sets for Localised, Locally Advanced, Metastatic, and Nonmetastatic Castration-resistant Prostate Cancer: An Update from the PIONEER Consortium. Eur Urol 2022;81:503-14. Improving the Methodological Quality of Prostate Cancer Core Outcome Sets in Future Updates

AU - Beyer, Katharina

AU - MacLennan, Steven

AU - Van Hemelrijck, Mieke

PY - 2022/9/1

Y1 - 2022/9/1

N2 - We thank Lei et al for their interest in our manuscript [1] and would like to take the opportunity to clarify their concerns regarding our methodology.

AB - We thank Lei et al for their interest in our manuscript [1] and would like to take the opportunity to clarify their concerns regarding our methodology.

KW - Abiraterone Acetate

KW - Humans

KW - Male

KW - Outcome Assessment, Health Care

KW - Prostatic Neoplasms

KW - Prostatic Neoplasms, Castration-Resistant

U2 - 10.1016/j.eururo.2022.05.014

DO - 10.1016/j.eururo.2022.05.014

M3 - Letter

C2 - 35688663

SN - 0302-2838

VL - 82

SP - e68-e69

JO - European Urology

JF - European Urology

IS - 3

ER -